Yvonne McGrath - May 17, 2021 Form 4 Insider Report for iTeos Therapeutics, Inc. (ITOS)

Role: VP, Research and Development
Signature: /s/ Michel Detheux, as Attorney-in-Fact
Stock symbol: ITOS
Transactions as of: May 17, 2021
Transactions value $: -$162,192
Form type: 4
Date filed: 5/19/2021, 04:14 PM
Next filing: Jun 3, 2021

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ITOS	Common Stock	Options Exercise	$33.5K	+7.93K		$4.23	7.93K	May 17, 2021	Direct
transaction	ITOS	Common Stock	Sale	-$142K	-5.81K	-73.27%	$24.41	2.12K	May 17, 2021	Direct	F1, F2
transaction	ITOS	Common Stock	Sale	-$51.6K	-2.03K	-95.75%	$25.43	90	May 17, 2021	Direct	F1, F3
transaction	ITOS	Common Stock	Sale	-$2.34K	-90	-100%	$26.01	0	May 17, 2021	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ITOS	Stock Option (Right to Buy)	Options Exercise	$0	-7.93K	-6.25%	$0.00	119K	May 17, 2021	Common Stock	7.93K	$4.23	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 15, 2021. The proceeds of the sales are being used to satisfy the payment of Belgian tax obligations in connection with the grant of a stock option to the reporting person on March 1, 2021.
F2	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.17 to $24.90, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F3	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.95, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F4	One-fourth of the shares subject to the stock option vest on the one-year anniversary of the vesting commencement date, subject to the reporting persons continuous service relationship with the Issuer through such date. Thereafter, 1/48 of the shares subject to the stock option vest on a monthly basis following the one-year anniversary of the vesting commencement date, subject to the reporting persons continuous service relationship with the Issuer through each applicable vesting date.